PDI signs four-year deal with Novartis

Share this article:
Contract sales firm PDI signed a four-year agreement with Novartis to deploy a field force promoting Elidel, a second-line eczema treatment for patients older than 2 years, according to Kim Golodetz, a spokesperson for PDI. 

The deal calls for deployment of “approximately 100 full-time equivalent sales representatives who will call upon physicians nationwide,” a PDI statement said. 

After losing contracts with GlaxoSmithKline and Sanofi-Aventis in 2006, PDI rebounded with a “top-five pharmaceutical company” contract in 2007.  

In February, the company named Peter Tilles president of its TVG marketing research and consulting unit.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.